Stockreport

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Inc.  (CRVO) 
PDF - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); [Read more]